bevacizumab

Type: Keyphrase
Name: bevacizumab
First reported 11 hours ago - Updated 11 hours ago - 1 reports

ASHP Asks Genentech to Reconsider Distribution Change, Calls for Stakeholder Meeting

A planned change to the distribution system for bevacizumab, trastuzumab, and rituximab could adversely impact patient care, ASHP CEO Paul W. Abramowitz  told Genentech CEO Ian T. Clark today.ASHP noted that the current supply chain effectively addresses ... [Published ASHP - 11 hours ago]
First reported 15 hours ago - Updated 15 hours ago - 1 reports

Adding drugs to standard chemotherapy improves response in triple-negative breast cancer

Share this article:Adding carboplatin and/or bevacizumab to the standard treatment regimen significantly improved pathologic complete response rates in patients with triple-negative breast cancer, according to a new phase 2 study.Because of its rapid ... [Published Chemotherapy Advisor - 15 hours ago]
First reported Oct 01 2014 - Updated Oct 01 2014 - 2 reports

[Correspondence] Bevacizumab alone or in combination with chemotherapy in glioblastomas?–Authors' reply

The BELOB trial was the first properly controlled trial on the use of bevacizumab in patients with recurrent glioblastoma, with a focus on survival.1 The trial results do not support further studies on the use of single-agent bevacizumab in this situation, ... [Published Lancet Oncology - Oct 01 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

Expanded Mutation Analysis Fails to Resolve Targeted Therapy Quandary in Metastatic CRC

Heinz-Josef Lenz, MDAll patients with metastatic colorectal cancer should undergo RAS mutation testing to ensure optimal patient selection for EGFR inhibitor therapy, according to a study 1 reported at the 2014 ESMO Congress meeting held in Madrid, S ... [Published OncLive - Sep 30 2014]
First reported Sep 29 2014 - Updated Sep 30 2014 - 1 reports

Cediranib Shows Potential in Advanced Cervical Cancer

MADRID — Adding the investigational agent cediranib (under development by AstraZeneca) to standard chemotherapy might be beneficial for patients with metastatic or recurrent cervical cancer, according to the phase 2 CIRCCa study, presented here at the ... [Published General Medicine eJournal - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Protein Content in Compounded Bevacizumab Varies Considerably

Reuters Health InformationBy David DouglasSeptember 29, 2014NEW YORK (Reuters Health) - The protein concentration of bevacizumab prepared by U.S. compounding pharmacies for intravitreal injection shows significant variations, according to New York-based ... [Published General Medicine eJournal - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

ROCHE BEARER SHARE : presents preliminary combination data for anti-PDL1 medicine (MPDL3280A) with Avastin (bevacizumab)

Roche presents preliminary combination data for anti-PDL1 medicine (MPDL3280A) with Avastin (bevacizumab) Early data indicate the combination with Avastin in first line metastatic renal cell carcinoma (mRCC) is safe and well tolerated Monotherapy MPDL3280A ... [Published 4 Traders - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Cancer-fighting cocktail demonstrates promising results as treatment for advanced cervical cancer

By a News Reporter-Staff News Editor at Cancer Vaccine Week Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by ... [Published Pharmacy Choice - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Cheaper Drug for Macular Degeneration

Neovascular macular degeneration is a progressive and chronic disease of the eye, and a leading cause of blindness in older people. About one in 10 people with macular degeneration suffers legal blindness. Bevacizumab is a drug that has been developed ... [Published ThirdAge - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Comment Bevacizumab beyond progression in breast cancer

Angiogenesis is the sprouting of new blood vessels from pre-existing ones, and is considered to be a prerequisite for the growth of both primary tumours and metastases. VEGF is a crucial factor involved in angiogenesis. Suppression of VEGF signalling ... [Published BioPortfolio - Sep 29 2014]
First reported Sep 28 2014 - Updated Sep 28 2014 - 2 reports

Biothera to Present Late-Breaking Data from Its Phase 2

Biothera will present today results on its investigational immunotherapy Imprime PGG ® in combination with standard of care frontline chemotherapy and bevacizumab in patients with stage IV nonsquamous non-small cell…Click to Continue » ... [Published Fort Mills Times - Sep 28 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Bevacizumab/Capecitabine Combo Shows Promise in Women With HER2-Negative Metastatic Breast Cancer

Phase III trials demonstrate improved survivalPositive results have been reported from the phase III IMELDA study, which showed that the combination of bevacizumab (Avastin, Genentech) plus capecitabine (Xeloda, Genentech) chemotherapy as maintenance ... [Published PT Community - Sep 26 2014]

Quotes

"Overall prognosis for women with this type of breast cancer remains inferior to that of other breast cancer subtypes, with higher risk of early relapse" Sikov said
"The FDA recently approved the use of bevacizumab as it completely changed clinical practice," Poveda added. "We are now waiting for phase III results to confirm the favorable predictions of this treatment with cediranib."
Nevertheless, concluded Dr. Kiss, the finding "casts doubt on the trustworthiness of the bevacizumab currently being compounded for intraocular use by mostly unregulated pharmacies nationwide."
Dr. Symonds said that his team plans to conduct an individual patient analysis to look at outcome and VGEF levels. "We will also be looking at different biomarkers. We want to find out why a significant number of patients live far longer than we thought they would" he reported

More Content

All (309) | News (264) | Reports (0) | Blogs (39) | Audio/Video (0) | Fact Sheets (0) | Press Releases (4)
sort by: Date | Relevance
ASHP Asks Genentech to Reconsider Distribution... [Published ASHP - 11 hours ago]
Adding drugs to standard chemotherapy improves ... [Published Chemotherapy Advisor - 15 hours ago]
Perspectives on Liver Masses [Published Diabetes Care - 21 hours ago]
[Corrections] Correction to Lancet Oncol 2014; ... [Published Lancet Oncology - Oct 01 2014]
[Correspondence] Bevacizumab alone or in combin... [Published Lancet Oncology - Oct 01 2014]
[Correspondence] Bevacizumab alone or in combin... [Published Lancet Oncology - Oct 01 2014]
Neutralization of Schwann Cell-Secreted VEGF Is... [Published Plosone.org - Sep 30 2014]
Durable Responses Observed with Nivolumab in Pr... [Published OncLive - Sep 30 2014]
Expanded Mutation Analysis Fails to Resolve Tar... [Published OncLive - Sep 30 2014]
Adding cediranib to chemotherapy improves progr... [Published Medical News Today - Sep 30 2014]
Can Biocon Join The $1-billion Club By 2018? [Published Forbes India - Sep 30 2014]
ESMO 2014: Activity of Second-Line Dovitinib in... [Published Health Canal - Sep 30 2014]
Cediranib Delays Disease Progression in Advance... [Published Cancernetwork.com - Sep 29 2014]
Patient access to orphan drugs faces new set of... [Published Formulary Journal - Sep 29 2014]
Protein Content in Compounded Bevacizumab Varie... [Published General Medicine eJournal - Sep 29 2014]
Cediranib Shows Potential in Advanced Cervical ... [Published General Medicine eJournal - Sep 29 2014]
Japan: IP High Court gives new ruling on patent... [Published Managing IP - Sep 29 2014]
ROCHE BEARER SHARE : presents preliminary combi... [Published 4 Traders - Sep 29 2014]
Studies from Mayo Clinic Yield New Information ... [Published Pharmacy Choice - Sep 29 2014]
Cancer-fighting cocktail demonstrates promising... [Published Pharmacy Choice - Sep 29 2014]
Regorafenib in Gastrointestinal Stromal Tumors [Published General Medicine eJournal - Sep 29 2014]
Cheaper Drug for Macular Degeneration [Published ThirdAge - Sep 29 2014]
Comment Bevacizumab beyond progression in breas... [Published BioPortfolio - Sep 29 2014]
Cediranib Combined With Chemotherapy Improves P... [Published OncLive - Sep 28 2014]
Biothera to Present Late-Breaking Data from Its... [Published Fort Mills Times - Sep 28 2014]
Biothera to Present Late-Breaking Data from Its... [Published Business Wire Health News - Sep 28 2014]
ESMO 2014: Adding cediranib to chemo improves P... [Published Ecancer Medicalscience - Sep 28 2014]
EU Panel Likes 4 New Cancer Products [Published American Journal of Public Health - Sep 26 2014]
Bevacizumab/Capecitabine Combo Shows Promise in... [Published PT Community - Sep 26 2014]
Metastatic Colorectal Cancer: Therapy Update fr... [Published Oncology Times - Sep 26 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Biothera to Present Late-Breaking Data from Its... [Published Business Wire Health News - Sep 28 2014]
EAGAN, Minn.--(BUSINESS WIRE)--Biothera will present today results on its investigational immunotherapy Imprime PGG® in combination with standard of care frontline chemotherapy and bevacizumab in patients with stage IV nonsquamous non-small cell lung ...
Roche’s Avastin plus chemotherapy gets FDA appr... [Published PBR - News - Aug 18 2014]
Roche has received approval from the US Food and Drug Administration (FDA) for Avastin (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan to treat women with persistent, recurrent or metastatic carcinoma of the cer ...
Avastin Wins FDA OK for Cervical Cancer [Published MedPageToday.com - medical news plus CME for ph ... - Aug 15 2014]
WASHINGTON (MedPage Today) -- The FDA has approved the angiogenesis inhibitor bevacizumab for treatment of advanced cervical cancer in combination with chemotherapy. ...
FDA Approves Genentech’s Avastin Plus Chemother... [Published EON Consumer - Aug 14 2014]
SOUTH SAN FRANCISCO, Calif.--(EON: Enhanced Online News)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with paclitaxel ...
FDA Approves Genentech’s Avastin Plus Chemother... [Published Business Wire Health News - Aug 14 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with paclitaxel and cisplatin ...
1 2 3 4 5 6 7 8

Press Releases

sort by: Date | Relevance
TRACON Pharmaceuticals Announces Results From C... [Published GlobeNewswire: Acquisitions News - Sep 24 2014]
Positive data from an additional 5 patients in ... [Published GlobeNewswire: Advertising News - Aug 26 2014]
PledPharma AB (publ) Interim report first quart... [Published GlobeNewswire: Acquisitions News - Apr 25 2014]
Go-ahead for PledPharma to also include Avastin... [Published GlobeNewswire: Advertising News - Apr 23 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.